Clinical trials: Affective Disorder
- Condition Affective Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Depressive Disorder and Anxiety Disorders
First Time in Human Study
This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers
- Trial name
- FTIM (NCT01031186)
- Testing
- GSK356278
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects
The Safety, Tolerability and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Male and Female Subjects
- Trial name
- NCT04591301
- Testing
- HEC113995 PA•H2O tablets
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Depression, Depression, Postpartum
TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety
This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of…
- Conditions
- Depression, Depression, Postpartum, Anxiety in Pregnancy, Anxiety
- Trial name
- NCT06364488
- Testing
- TrueBlue App
- Where
- 2 sites in United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- BlueSkeye AI
Bipolar Disorder, Depression
A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)
This is a subject blind, investigator and sponsor open, randomized study consisting of 2 parts. Up to 15 healthy subjects will be included in the study.
- Trial name
- NCT00939887
- Testing
- PF-04455242
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Anxiety, Depression
Ginger.io Behavioral Health Study
This Study will evaluate the impact of a smartphone-based platform on a range of outcomes for medically-underserved patients with mood disorders (e.g.
- Conditions
- Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT02491307
- Testing
- Ginger.io Smartphone Application
- Where
- 4 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Community Health Center, Inc.
Depression
Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Trial name
- NCT00329147
- Testing
- desvenlafaxine SR, desipramine, paroxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
The objectives of this study were to examine the cardiovascular sensitivity to oral tyramine after establishment of steady state with CX157 Modified Release (MR) Tablets, 125 mg administered twice per day (BID) in healthy…
- Trial name
- CX157-112 (NCT01633437)
- Testing
- CX157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CeNeRx BioPharma Inc.
Schizophrenia, Hepatic Impairment
A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
The purpose of this study is 1) to investigate the single-dose pharmacokinetics of immediate release (IR) paliperidone, after oral administration, in patients having moderate hepatic impairment compared to patients having normal…
- Trial name
- NCT00791284
- Testing
- Intermediate release (IR) Paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder (MDD)
Scopolamine in Healthy Volunteers
This single-site clinical trial is an open-label study to identify the safety and pharmacokinetics of DPI-386 Nasal Gel (intranasal scopolamine gel) and IV Scopolamine.
- Trial name
- NCT03874130
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Major Depressive Disorder
Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
This study was a pharmacokinetic and safety evaluation of the S-adenosylmethionine formulation MSI-195, and a commercial comparator. The study was broken into two stages.
- Trial name
- NCT04623034
- Testing
- Ademetionine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- MSI Methylation Sciences, Inc.
Depressive Disorder
Paxil CR Bioequivalence Study Brazil
The study is prospective, open, randomized, crossover in steady state and the volunteers received multiple doses of the drug test and reference (two periods of drug administration).
- Trial name
- NCT01316926
- Testing
- Test formulation, Reference formulation
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers
This is a First Time in Human Study to assess the safety, tolerability, pharmacokinetics and resting motor threshold (rMT) of single doses of GSK drug in healthy volunteers.This will be a 2 part and 2 centre study.Part 1 will be…
- Trial name
- NCT00488566
- Testing
- GSK drug, Lamictal
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biogen
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants
This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.
- Trial name
- NCT01380691
- Testing
- LY2216684, Alcoholic beverage
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Bipolar Depression, Bipolar Disorder
Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.
GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in animal models. This study is being conducted to obtain information regarding the safety, tolerability and pharmacokinetics of repeated doses…
- Trial name
- NCT00908154
- Testing
- GSK1014802
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Biogen
Major Depressive Disorder
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
The main purpose of this study is to evaluate the effect of desvenlafaxine administered as DVS SR on the pharmacokinetics of midazolam in healthy male and female subjects.
- Trial name
- NCT00952653
- Testing
- Desvenlafaxine Succinate Sustained Release, Midazolam
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
This is a study to assess the distribution, metabolism and excretion of [14C]AZD6765 after a single-dose intravenous administration.
- Trial name
- AZD6765 (NCT01217645)
- Testing
- 150 mg [14C] AZD6765
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Bipolar Disorder
Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose…
- Trial name
- NCT00602394
- Testing
- Lithium
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Schizophrenia
A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
The purposes of this study are to investigate the metabolic pathways of paliperidone and excretion of paliperidone and its metabolites in healthy adult male volunteers, both CYP2D6 poor and extensive metabolizers, after…
- Trial name
- NCT00796029
- Testing
- 14C-paliperidone
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.